Effect of Screening for Type 2 Diabetes on Risk of Cardiovascular Disease and Mortality: a Controlled Trial Among 139,075 Individuals Diagnosed with Diabetes in Denmark Between 2001 and 2009

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2017 Aug 24

PMID 28831539

Citations 36

Authors

Rebecca K Simmons

Simon J Griffin

Torsten Lauritzen

Annelli Sandbaek

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: There is continuing debate about the net benefits of population screening for type 2 diabetes. We compared the risk of cardiovascular disease (CVD) and mortality among incident cases of type 2 diabetes in a screened group with those in an unscreened group.

Methods: In this register-based non-randomised controlled trial, eligible individuals were all men and women aged 40-69 years without known diabetes, registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006, 153,107 individuals registered with 181 practices participating in the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes-risk-score questionnaire. Individuals at moderate-to-high risk were invited to visit their family doctor for assessment of diabetes status and cardiovascular risk (screening group). The 1,759,285 individuals registered with all other practices in Denmark constituted the retrospectively constructed no-screening (control) group. In this post hoc analysis, we identified individuals from the screening and no-screening groups who were diagnosed with diabetes between 2001 and 2009 (n = 139,075), and compared risk of CVD and mortality in these groups between 2001 and 2012.

Results: In the screening group, 27,177/153,107 (18%) individuals attended for screening, of whom 1533 were diagnosed with diabetes. Between 2001 and 2009, 13,992 people were newly diagnosed with diabetes in the screening group (including those diagnosed by screening) and 125,083 in the no-screening group. Between 2001 and 2012, the risks of CVD and mortality were lower among individuals with diabetes in the screening group compared with individuals with diabetes in the no-screening (control) group (CVD HR 0.84, 95% CI 0.80, 0.89; mortality HR 0.79, 95% CI 0.74, 0.84).

Conclusions/interpretation: A single round of diabetes screening and cardiovascular risk assessment in middle-aged Danish adults in general practice was associated with a significant reduction in risk of all-cause mortality and CVD events in those diagnosed with diabetes.

Citing Articles

Impact of Population-Based Screening for Diabetes and Prediabetes Among 67-Year-Olds Using Point-of-Care HbA1c on Healthcare Ultilisation, Results from the VISP Cohort.

Andersen J, Hogh A, Lindholt J, Sogaard R, Stovring H, Yderstraede K Clin Epidemiol. 2025; 17:75-85.

PMID: 39926308 PMC: 11807345. DOI: 10.2147/CLEP.S487825.

Evaluation of a Diabetes Screening Clinical Decision Support Tool.

Tseng E, Stein A, Wang N, Mathioudakis N, Yeh H, Maruthur N AJPM Focus. 2024; 3(6):100287.

PMID: 39582738 PMC: 11582736. DOI: 10.1016/j.focus.2024.100287.

Assessing Elevated Blood Glucose Levels Through Blood Glucose Evaluation and Monitoring Using Machine Learning and Wearable Photoplethysmography Sensors: Algorithm Development and Validation.

Shi B, Dhaliwal S, Soo M, Chan C, Wong J, Lam N JMIR AI. 2024; 2:e48340.

PMID: 38875549 PMC: 11041426. DOI: 10.2196/48340.

Feasibility of a Type 2 Diabetes Prevention Program at Nationwide Level in General Practice: A Pilot Study in Italy.

La Grotta R, Pellegrini V, Prattichizzo F, Amata O, Panella L, Frizziero A J Clin Med. 2024; 13(4).

PMID: 38398440 PMC: 10888610. DOI: 10.3390/jcm13041127.

A follow-up cohort study on the risk of prediabetes, comparing women with previous preeclamptic or normotensive pregnancies.

Moller L, Bladh M, Brismar K, Palm K, Andolf E Sci Rep. 2023; 13(1):16427.

PMID: 37777568 PMC: 10542795. DOI: 10.1038/s41598-023-43014-z.

References

Siu A . Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015; 163(11):861-8. DOI: 10.7326/M15-2345. View

Rahman M, Simmons R, Hennings S, Wareham N, Griffin S . How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia. 2012; 55(6):1651-9. DOI: 10.1007/s00125-011-2441-9. View

Griffin S, Borch-Johnsen K, Davies M, Khunti K, Rutten G, Sandbaek A . Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011; 378(9786):156-67. PMC: 3136726. DOI: 10.1016/S0140-6736(11)60698-3. View

Simmons R, Echouffo-Tcheugui J, Sharp S, Sargeant L, Williams K, Prevost A . Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012; 380(9855):1741-8. PMC: 3607818. DOI: 10.1016/S0140-6736(12)61422-6. View

Simmons R, Griffin S, Witte D, Borch-Johnsen K, Lauritzen T, Sandbaek A . Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia. 2017; 60(11):2183-2191. PMC: 6086322. DOI: 10.1007/s00125-017-4323-2. View

Alberti K, Zimmet P . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539-53. DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. View

Safwat S, Ishak R, Hathout R, Mortada N . Statins anticancer targeted delivery systems: re-purposing an old molecule. J Pharm Pharmacol. 2017; 69(6):613-624. DOI: 10.1111/jphp.12707. View

Christensen J, Sandbaek A, Lauritzen T, Borch-Johnsen K . Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia. 2004; 47(9):1566-73. DOI: 10.1007/s00125-004-1496-2. View

Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J . Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010; 375(9723):1365-74. DOI: 10.1016/S0140-6736(09)62162-0. View

10.

Eborall H, Griffin S, Prevost A, Kinmonth A, French D, Sutton S . Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007; 335(7618):486. PMC: 1971192. DOI: 10.1136/bmj.39303.723449.55. View

11.

Conroy R, Pyorala K, Fitzgerald A, Sans S, Menotti A, De Backer G . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11):987-1003. DOI: 10.1016/s0195-668x(03)00114-3. View

12.

Prasad V, Lenzer J, Newman D . Why cancer screening has never been shown to "save lives"--and what we can do about it. BMJ. 2016; 352:h6080. DOI: 10.1136/bmj.h6080. View

13.

Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K . A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004; 27(3):727-33. DOI: 10.2337/diacare.27.3.727. View

14.

Chang H, Kuo H, Tung T, Chou P, Chen T . Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med. 2000; 31(4):396-402. DOI: 10.1006/pmed.2000.0728. View

15.

Green A, Sortso C, Jensen P, Emneus M . Validation of the danish national diabetes register. Clin Epidemiol. 2015; 7:5-15. PMC: 4274151. DOI: 10.2147/CLEP.S72768. View

16.

Andy Schuetz C, Alperin P, Guda S, van Herick A, Cariou B, Eddy D . A standardized vascular disease health check in europe: a cost-effectiveness analysis. PLoS One. 2013; 8(7):e66454. PMC: 3712021. DOI: 10.1371/journal.pone.0066454. View

17.

Engelgau M, Narayan K, Herman W . Screening for type 2 diabetes. Diabetes Care. 2000; 23(10):1563-80. DOI: 10.2337/diacare.23.10.1563. View

18.

Harris M, Klein R, Welborn T, Knuiman M . Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992; 15(7):815-9. DOI: 10.2337/diacare.15.7.815. View

19.

Porta M, Curletto G, Cipullo D, Rigault de la Longrais R, Trento M, Passera P . Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care. 2014; 37(6):1668-74. DOI: 10.2337/dc13-2101. View

20.

Kuo H, Chang H, Chou P, Teng L, Chen T . A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol. 1999; 28(2):233-40. DOI: 10.1093/ije/28.2.233. View